Registration Dossier

Administrative data

Endpoint:
basic toxicokinetics
Type of information:
other: expert statement
Adequacy of study:
key study
Study period:
2012-06-29
Reliability:
1 (reliable without restriction)
Rationale for reliability incl. deficiencies:
other: Evaluation of toxicokinetic behaviour based on structure and physico-chemical properties of the substance.

Data source

Reference
Reference Type:
other: expert statement
Title:
Unnamed
Year:
2012
Report Date:
2012

Materials and methods

Objective of study:
toxicokinetics
Principles of method if other than guideline:
Assessment of toxicokinetic behaviour
GLP compliance:
no

Test material

Reference
Name:
Unnamed
Type:
Constituent
Details on test material:
technical product

Results and discussion

Applicant's summary and conclusion

Conclusions:
Interpretation of results (migrated information): other: bioaccumulation not to be expected because of the low logPow
MPAAU is expected to have good bioavailability after uptake via the oral and inhalation route. Based on data of an in-vitro dermal penetration test the bioavailability via the dermal route is low (<5%). MPAAU as well as so far unidentified metabolites are expected to be widely distributed in the organism without potential of bioaccumulation. Excretion via urine is regarded to be the preferred way of elimination.
There are indications from available toxicity studies that MPAAU was absorbed and distributed systemically when administered orally. Short-term toxicity studies with relatively large doses of MPAAU suggest that absorbed MPAAU and potential metabolites are rapidly eliminated without impact to the test animals. MPAAU and its potential metabolites do not present a genotoxic hazard and do not cause significant toxicity in animals.
Bioaccumulation is not expected because of the low log Pow.